Optimi Health Corp. announced that it has entered into a long-term distribution agreement with Mind Medicine Australia (“MMA”), to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules. Under the signed Purchase Order, Optimi has agreed to export products to Australia by July 1, 2023, when authorized psychiatrists can begin prescribing MDMA and psilocybin for specific mental health conditions through the Authorised Prescriber's Scheme of the country's Therapeutic Goods Administration (TGA).

The agreement also gives MMA the option to arrange the supply of additional doses as they determine market demand. Products earmarked for the Australian market will be manufactured, encapsulated, and packaged entirely inside of Optimi's Health Canada Licensed Facility under GMP compliant protocols, and will follow Health Canada's Controlled Substances Export laws.  The Company has been contracted to continue supplying OPTI-MHCL and GMP psilocybin capsules under the arrangements with MMA on an ongoing basis, as Australia begins the implementation of its expanded therapeutic psychedelic access for patients suffering from post-traumatic stress disorders and treatment-resistant depression. Supplies will be coordinated through a network of pharmacists in each State and Territory of Australia and are subject to all regulatory approvals being obtained.

Throughout the Company's 2022 Year of Commercialization, Optimi maintained steady communication with MMA in anticipation of meaningful developments resulting from the organization's tireless advocacy on behalf of patients.